VBL Therapeutics to Present Data on its Novel VB-600 Platform at Keystone Conference on February 26
February 19 2019 - 8:00AM
VBL Therapeutics (Nasdaq: VBLT), today announces that the Company
will present new data on the potential of its VB-600 platform
targeting MOSPD2 for inflammatory and oncology indications, at the
Keystone Symposia on Myeloid Cells, to be held February 24—28, 2019
at the Eldorado Hotel & Spa in Santa Fe, New Mexico.
Oral Presentation Details: |
|
|
Title: |
|
MOSPD2: Key Regulator
of Myeloid Cell Migration and a Novel Target for Treatment of
Inflammatory Diseases |
Presenter: |
|
Itzhak Mendel, PhD |
Date: |
|
Tuesday, February 26,
2019 |
Time: |
|
8:00 – 11:00 AM
MST |
Session: |
|
Myeloid Cells in
Metabolic and Inflammatory Diseases |
Location: |
|
Eldorado Grand
Ballroom |
|
|
|
Poster Presentation
Details: |
|
|
Abstract: |
|
MOSPD2: Key Regulator
of Myeloid Cell Migration and a Novel Target for Treatment of
Inflammatory Diseases |
Session
title: |
|
Poster Session 2 |
Date: |
|
Tuesday, February 26,
2019 |
Time: |
|
7:30 - 10:00 PM
MST |
Poster #: |
|
2028 |
For more information on the Keystone Symposium on Myeloid Cells,
including a detailed program, refer to
http://www.keystonesymposia.org/index.cfm?e=web.Meeting.Program&meetingid=1553
About VBL's VB-600 Platform
VBL is conducting two parallel drug development programs that
are exploring the potential of MOSPD2, a protein that VBL has
identified as a key regulator of cell motility, as a therapeutic
target for inflammatory diseases and cancer. Our VB-600 platform
comprises classical anti-MOSPD2 monoclonal antibodies for
inflammatory indications, as well as bi-specific antibody
candidates for oncology.
About VBL
Vascular Biogenics Ltd., operating as VBL Therapeutics, is a
clinical stage biopharmaceutical company focused on the discovery,
development and commercialization of first-in-class treatments for
cancer. The Company’s lead oncology product candidate, ofranergene
obadenovec (VB-111), is a first-in-class, targeted anti-cancer
gene-therapy agent that is positioned to treat a wide range of
solid tumors. It is conveniently administered as an IV infusion
once every two months. It has been observed to be well-tolerated in
>300 cancer patients and demonstrated efficacy signals in an
“all comers” Phase 1 trial as well as in three tumor-specific Phase
2 studies. Ofranergene obadenovec is currently being studied in a
potential registration trial for platinum-resistant ovarian
cancer.
Forward Looking Statements
This press release contains forward-looking statements. All
statements other than statements of historical fact are
forward-looking statements, which are often indicated by terms such
as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,”
“intend,” “look forward to,” “may,” “plan,” “potential,” “predict,”
“project,” “should,” “will,” “would” and similar expressions. These
forward-looking statements include, but are not limited to,
statements regarding our programs, including VB-111, including
their clinical development, such as the timing thereof, therapeutic
potential and clinical results, and the scope and protection of our
intellectual property rights. These forward-looking statements are
not promises or guarantees and involve substantial risks and
uncertainties. Among the factors that could cause actual results to
differ materially from those described or projected herein include
uncertainties associated generally with research and development,
clinical trials and related regulatory reviews and approvals, the
risk that historical clinical trial results may not be predictive
of future trial results, and that we may not realize the expected
benefits of our intellectual property protection. A further list
and description of these risks, uncertainties and other risks can
be found in the Company’s regulatory filings with the U.S.
Securities and Exchange Commission, including in our annual report
on Form 20-F for the year ended December 31, 2017, and subsequent
filings with the SEC. Existing and prospective investors are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof. VBL
Therapeutics undertakes no obligation to update or revise the
information contained in this press release, whether as a result of
new information, future events or circumstances or otherwise.
INVESTOR CONTACT:Michael RiceLifeSci Advisors,
LLC(646) 597-6979
Vascular Biogenics (NASDAQ:VBLT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Vascular Biogenics (NASDAQ:VBLT)
Historical Stock Chart
From Apr 2023 to Apr 2024